First Wave BioPharma, Inc.
Symbool: FWBI
NASDAQ
2.82
USDMarktprijs vandaag
-0.2784
Koers/Winst Verhouding
0.0000
Koers/Winst Groei Verhouding
5.71M
MRK Kapitalisatie
- 0.00%
DIV Rendement
First Wave BioPharma, Inc. (FWBI) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 10.3 | 3.7 | 1.4 | 8.2 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 0.02 | 0 | 0.1 | 0 | ||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-current-assets | 4.49 | 1.2 | 2 | 1176268 | ||||||||||
balance-sheet.row.total-current-assets | 14.82 | 5 | 3.4 | 9.4 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0.98 | 0.2 | 0.3 | 0.4 | ||||||||||
balance-sheet.row.goodwill | 6.74 | 1.7 | 1.7 | 1.9 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 6.74 | 1.7 | 1.7 | 1.9 | ||||||||||
balance-sheet.row.long-term-investments | 0.09 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.tax-assets | -0.06 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.other-non-current-assets | 0.12 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-non-current-assets | 7.86 | 1.9 | 2 | 2.4 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 22.67 | 6.9 | 5.4 | 11.8 | ||||||||||
balance-sheet.row.account-payables | 3.19 | 0.6 | 0.7 | 2.7 | ||||||||||
balance-sheet.row.short-term-debt | 1.41 | 0.7 | 0.7 | 0.7 | ||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.long-term-debt-total | 0.69 | 0.1 | 0.2 | 0.3 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 2.58 | 0.8 | 1.1 | 8 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0.69 | 0.1 | 0.2 | 7.3 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0.89 | 0.1 | 0.3 | 0.4 | ||||||||||
balance-sheet.row.total-liab | 12.2 | 3.3 | 2.7 | 19.6 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.retained-earnings | -713.95 | -184.3 | -168.5 | -153.9 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | -1.2 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 724.43 | 187.9 | 171.3 | 147.3 | ||||||||||
balance-sheet.row.total-stockholders-equity | 10.48 | 3.6 | 2.7 | -7.8 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 22.67 | 6.9 | 5.4 | 11.8 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | 10.48 | 3.6 | 2.7 | -7.8 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 22.67 | - | - | - | ||||||||||
Total Investments | 0.09 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-debt | 2.1 | 0.8 | 0.9 | 1 | ||||||||||
balance-sheet.row.net-debt | -8.2 | -2.9 | -0.5 | -7.2 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -15.79 | -15.8 | -14.6 | -58.5 | |||||||||
cash-flows.row.depreciation-and-amortization | 0.03 | 0 | 0 | 0.5 | |||||||||
cash-flows.row.deferred-income-tax | -0.17 | 0.2 | 0 | 3.8 | |||||||||
cash-flows.row.stock-based-compensation | 1.04 | 1 | 0.8 | 1.4 | |||||||||
cash-flows.row.change-in-working-capital | 2.19 | 2.2 | -10.5 | 17.1 | |||||||||
cash-flows.row.account-receivables | 0.09 | 0.1 | -0.1 | 0.6 | |||||||||
cash-flows.row.inventory | 0.75 | 0 | 0.1 | -0.6 | |||||||||
cash-flows.row.account-payables | -0.17 | -0.2 | -2 | 1.4 | |||||||||
cash-flows.row.other-working-capital | 1.51 | 2.3 | -8.5 | 15.7 | |||||||||
cash-flows.row.other-non-cash-items | 0.32 | 0 | 2 | 3.5 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -12.38 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.debt-repayment | -0.6 | -0.6 | -0.6 | -507125 | |||||||||
cash-flows.row.common-stock-issued | 9.88 | 15.8 | 23 | 32.7 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 4000000 | |||||||||
cash-flows.row.dividends-paid | 0 | -0.3 | 0 | -4507125 | |||||||||
cash-flows.row.other-financing-activites | 6.04 | 15.4 | -6.6 | 1014262.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 15.23 | 15.2 | 15.7 | 44.8 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | -0.3 | 0 | |||||||||
cash-flows.row.net-change-in-cash | 2.35 | 2.3 | -6.9 | 2.2 | |||||||||
cash-flows.row.cash-at-end-of-period | 10.37 | 3.7 | 1.4 | 8.2 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 8.02 | 1.4 | 8.2 | 6.1 | |||||||||
cash-flows.row.operating-cash-flow | -12.38 | -12.4 | -22.3 | -32.3 | |||||||||
cash-flows.row.capital-expenditure | -0.5 | -0.5 | 0 | -10.3 | |||||||||
cash-flows.row.free-cash-flow | -12.88 | -12.9 | -22.3 | -42.6 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.cost-of-revenue | 0.08 | 0 | 0.1 | 0.5 | |||||||||
income-statement-row.row.gross-profit | -0.08 | 0 | -0.1 | -0.5 | |||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.research-development | 5.03 | - | - | - | |||||||||
income-statement-row.row.selling-general-administrative | 10.74 | - | - | - | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.01 | - | - | - | |||||||||
income-statement-row.row.other-expenses | 0 | 0 | -0.2 | 0.5 | |||||||||
income-statement-row.row.operating-expenses | 15.76 | 15.7 | 12.7 | 56.7 | |||||||||
income-statement-row.row.cost-and-expenses | 15.77 | 15.8 | 12.7 | 56.7 | |||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||
income-statement-row.row.interest-expense | 0.02 | 0 | 0 | 0 | |||||||||
income-statement-row.row.selling-and-marketing-expenses | -0.01 | - | - | - | |||||||||
income-statement-row.row.total-other-income-expensenet | -0.02 | 0 | -2 | 0.5 | |||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | -0.2 | 0.5 | |||||||||
income-statement-row.row.total-operating-expenses | -0.02 | 0 | -2 | 0.5 | |||||||||
income-statement-row.row.interest-expense | 0.02 | 0 | 0 | 0 | |||||||||
income-statement-row.row.depreciation-and-amortization | 0.03 | 0 | -0.2 | 3.4 | |||||||||
income-statement-row.row.ebitda-caps | -15.74 | - | - | - | |||||||||
income-statement-row.row.operating-income | -15.77 | -15.8 | -12.7 | -59.1 | |||||||||
income-statement-row.row.income-before-tax | -15.79 | -15.8 | -14.6 | -58.5 | |||||||||
income-statement-row.row.income-tax-expense | 0.02 | 0 | 2 | 0.5 | |||||||||
income-statement-row.row.net-income | -15.81 | -15.8 | -16.6 | -59.1 |
Vaak gestelde vragen
Wat is First Wave BioPharma, Inc. (FWBI) totale activa?
First Wave BioPharma, Inc. (FWBI) totale activa is 6883195.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.000.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is 0.000.
Wat is de totale omzet van de onderneming?
De totale opbrengst is 0.000.
Wat is First Wave BioPharma, Inc. (FWBI) nettowinst (netto-inkomen)?
De nettowinst is -15794983.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 826844.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 15741553.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 3711770.000.